| Literature DB >> 32102343 |
Aroa Lopez-Santamarina1, Jose Manuel Miranda1, Alicia Del Carmen Mondragon1, Alexandre Lamas1, Alejandra Cardelle-Cobas1, Carlos Manuel Franco1, Alberto Cepeda1.
Abstract
Human gut microbiota plays an important role in several metabolic processes and human diseases. Various dietary factors, including complex carbohydrates, such as polysaccharides, provide abundant nutrients and substrates for microbial metabolism in the gut, affecting the members and their functionality. Nowadays, the main sources of complex carbohydrates destined for human consumption are terrestrial plants. However, fresh water is an increasingly scarce commodity and world agricultural productivity is in a persistent decline, thus demanding the exploration of other sources of complex carbohydrates. As an interesting option, marine seaweeds show rapid growth and do not require arable land, fresh water or fertilizers. The present review offers an objective perspective of the current knowledge surrounding the impacts of seaweeds and their derived polysaccharides on the human microbiome and the profound need for more in-depth investigations into this topic. Animal experiments and in vitro colonic-simulating trials investigating the effects of seaweed ingestion on human gut microbiota are discussed.Entities:
Keywords: Chlorophyceae; Phaeophyceae; Rhodophyceae; polysaccharides; prebiotic; seaweed
Mesh:
Substances:
Year: 2020 PMID: 32102343 PMCID: PMC7070434 DOI: 10.3390/molecules25041004
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Prebiotic effect of different species of brown seaweed.
| Type of Study | Seaweed, Dosage and Time of Exposure | Polysaccharides Characterization | Significant Changes in Gut Microbiota | Significant Changes in Related Metabolites | Reference |
|---|---|---|---|---|---|
| In vitro fermentation system using fresh fecal samples from four healthy donors | Polysaccharides extracted from 20 g of | Total carbohydrate 42.3%; uronic acid 11%; protein 1.4% and sulfate content 23.9%; Monosaccharides content were composed of Man, GlcA, Glc, Gal, Xyl, and Fuc at a molar ratio of 16.65, 20.34, 1.60, 9.69, 3.44, and 48.29 | Increase in Bacteroidetes and Firmicutes. At genus level, increase of | Increase in SCFA, acetate and propionate in | [ |
| In vivo trials using 3 Wistar male rats per sample, comparing effect of | 0.2 g of polysaccharides extracted from | Crude polysaccharide contained carbohydrates 22.7%, sulphate content of 17.1% and protein content 1.34%. Hydrolysates showed 25.1–26.7% carbohydrates, 25.3–25% sulphate and 1.7–1.4% protein contents | Not provided | Increase in both acetic, propionic and butyric acids, in this order. SCFA were higher in the case of polysaccharides with lower molecular weight | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | 1% | Average molecular weight 31.0 and 56.0 kDa | No significant changes in GM | Increase in total SCFA, acetic and propionic acids | [ |
| In vivo trial using 18 male C57BL/6 mice. 6 mice received fucoidans extracted fro | 100 mg/kg/day of fucoidans obtained from | 21% sulfate content; 1330 KDa molecular weight; 7.3% Man, 24.1% GlcA, 1.5% Glc, 7.2% Gal, 1.3% Xyl, 58.6% Fuc | Fucoidans administration resulted in a much more diverse cecal microbiota, increase on | Fucoidans decreased the serum levels of lipopolysaccharide-binding protein | [ |
| In vitro fermentation system using fresh fecal samples from 3 healthy donors | 1.5% | 48.7% total fibre, 16.1% non-digestible non-starch polysaccharides, 1.3% total starch, 43% total sugar, 3.8% protein and 4.5% total phlotorannin | Increase of total bacteria, | Increase in total SCFA, acetic and propionic acids | [ |
| In vitro fermentation system using fresh fecal samples from three3 healthy donors | Polysaccharides extracts obtained by microwave-intensified enzymatic process from 4.5 g of crude | Crude extract fraction: 14.4%, fibre, 5.6% non-digestible non-starch polysaccharides, 20.6% sugar, 0.2% ManA, 0.5% Man, 17.2% Glc, 0.5% Gal, 0.3% Xyl, 1.8% Fuc, 4.6% phlorotannin. | Increase of | Total SCFA were higher in crude fraction than all other fractions after 24 h fermentation. All fractions except phlorotannin-enriched fraction significantly increased SCFA production with respect to negative controls | [ |
| High molecular weight polysaccharide-enriched fraction: 62.4% fibre, 22.8% non-digestible non-starch polysaccharides, 0.3% starch, 42.1% sugar, 1.9% GulA, 7.2% ManA, 2.1% Man, 1.1% GlcA, 17.1% Glc, 1.7% Gal, 1.5% Xyl, 9.4% Fuc, 1.7% phlorotannin. | |||||
| In vivo trail using 10 C57BL6 mice per group, with previously induced colitis by supplementing 3% | Fucoidans extracted from | Fucus-polyphenol: 40.2% neutral carbohydrates; 21.8% sulfates; 26.2% polyphenols; 3.6% uronic acids and 203.1 kDa peak molecular weight.High purity fucoidan: 59.5% neutral carbohydrates; 26.6% sulphates; <0.5% polyphenols; 1.4% uronic acids; 61.8 kDa molecular weight. | Not provided | Both oral fucoidan reduced cytokines associated with inflammatory bowel disease such as interleukin-1α, interleukin-1β, interleukin-10, macrophrage inflammatory protein-1α, macrophrage inflammatory protein-1β, granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | 0.8 g of fucoidans obtained from | Not provided | Decrease in | Decrease in pH and increase in lactic acid and SCFA, including acetic and butyic acids | [ |
| In vivo trial using 18 male C57BL/6 mice. Six mice received fucoidans extracted | 100 mg/kg/day of fucoidans obtained | Fucoidans from | Increase in the abundance of | Decreased in the serum levels of lipopolysaccharide-binding protein | [ |
| In vivo trial using six male Wistar rats per group | 2% | Not provided | Increase of | Increase organic acids, specially propionate, whereas decreased cecal putrefactive compounds (indole, phenol and H2S) | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors and an in vivo trial using 20 Wistar rats | 1 g laminarins from | Not provided | No significant differences were obtained in the in vitro trial for GM composition. | Increase in total SCFA in laminarin-added culture medium than in glucose-added. Laminarins supplementation increased the colon luminal content of mucin, while decreased luminal mucin in jejunum, ileum and caecum in rats | [ |
| In vivo trial using 28 female Sprague-Dawley rats | Supplementation with 10% of dried | Not provided | Reduction in Firmicutes to Bacteroidetes ratio and decrease of pathogenic bacteria such as | Increase in total SCFA, and butyric acid. Lower production of acetic acid propionic acids | [ |
| In vivo trial using six female BALB/C mice per group | Mice received normal diet, high-fat diet or high-fat diet added with laminarins at 1% | Not provided | Decrease in Firmicutes and increase in Bacteroidetes phylum, especially the genus | Mice fed with laminarin supplementation showed significantly higher CAZyme families in feces | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | Polysaccharides isolated from | Not provided | Increase | Increase in SCFA with respect to cellulose-added samples, but similar SCFA content or even lower with respect to FOS-added samples | [ |
| In vitro fermentation system with individual bifidobacteria including | Beta-glucans from | β-Glucan > 95%, protein 3%; monosaccharides: 98% Gluc; 2% Man. 6 kDa as average molecular weight | Increase of all | Increase of SCFA, acetic propionic and butyric acids and decrease of pH in a similar way of the other beta-glucans assayed | [ |
| In vitro fermentation system in cellular lines using human-enterocyte-like-29-Luc cells | Supplementation with 0.5% | Glu residues with degree of polymerization between 22 and 25 and 5 kDa as average molecular weight | Inhibition of | Not provided | [ |
| In vivo trial using 24 male C57BL/6J mice | Polysaccharides extracted from | Not provided | Increase of | Not provided | [ |
| In vivo trial using 16 male C57BL/6 mice fed with a high-fat diet | 5% | Not provided | Not provided | Reduced activity of fecal bile salt hydrolase activity and secondary bile acids | [ |
| In vivo trial using Syrian golden hamsters | 150 mg/kg body weight of | Sulfated oligosaccharide containing galactose, sulfated galactose, sulfated anhydrogalactose and methyl sulfated galactoside | Increased gut bacterial diversity in treated hamsters. Significant increase in | [ | |
| In vitro fermentation system using fresh fecal samples from three healthy donors | Extracts from | Not provided | Increase | Increase in SCFA and lactic acid production with respect to negative controls | [ |
| In vitro test comparing the growth of | 1% | 53.5% fiber, 13.2% protein, 2.3% fat, 28.9% ash. Content of Cel, Fru and Gluc (not specific proportions) | Prebiotic effect by 1.42-fold more growth stimulation of | Not provided | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | 200 mg polysaccharides extracted from | 68.3% carbohydrate; 0.3% protein; 3.5% sulfate: Monosaccharide molar ratio: 3.9% arabinose; 6.2% Gal, 3.2% Glc, 15.6% Xyl, 14.8% Man 15.6% GulA, 40.6% GlcA. Average molecular weight 4.8 kDa | Decrease of Firmicutes, while increase of Bacteroidetes and beneficial bacteria such as | Decrease of pH and increase in total SCFA and acetic, propionic, butiric and | [ |
| In vivo trial using 28 female Sprague-Dawley rats | Supplementation with 10% of dried | Not provided | Reduction in Firmicutes to Bacteroidetes ratio and decrease of pathogenic bacteria such as | Increase in total SCFA, and butyric acid. Lower production of acetic acid propionic acids | [ |
BCC: Biotec Culture Collection; BCC: British Culture Collection; Cel: Cellobiose; Gal: galactose; GlcA: galacturonic acid; Glc: glucose; GulA: guluronic acid; FOS: fructooligosaccharides; Fru: fructose; Fuc: fucose; JCM: Japan Collection of Microorganism; kDa: kilodaltons; ManA: Mannuronic acid; Man: mannose; MRS: Man, Rogosa and Sharpe; MTCC: Microbial Type Culture Collection and Gene Bank; NCIM: National Centre of Integrative Medicine; SCFA: Short chain fatty acids; Xyl: Xylose.
Prebiotic effect of different species of red seaweed.
| Type of Study | Seaweed and Dosage | Polysaccharides Characterization | Significant Changes in Gut Microbiota | Significant Changes in Metabolites | Reference |
|---|---|---|---|---|---|
| In vitro test comparing the growth of | 1% | 45.9% fiber, 10.9% protein, 1.6% fat, 39.4% ash. Only Glu was found as monosaccharide | Prebiotic effect by 0.84-fold more growth stimulation of | Not provided | [ |
| In vivo trial using male Sprague-Dawley rats (six per group) | Fed added with 0.5–2.5% ( | Not provided | Increase of | Increase in total SCFA and acetic, propionic and butiric acids in rats fed with | [ |
| In vitro test in MRS broth for | 0.1–0.5% | 62.1% sugar; 21.4% sulfate; Monosaccharides at molar ratio: 0.01 Man, 0.01 GluA, 1% Gal, 0.09% Xyl, 0.01% Fuc, 0.03% Glu | Increase in beneficial bacteria with better results at 0.1% concentration. No inhibition was detected against pathogens | Not provided | [ |
| In vitro test in MRS broth for | 0.1–0.4% | 41.9% sugar; 20.6% sulfate; Monosaccharides at molar ratio: 0.01 Man, 0.02 GluA, 1% Gal, 0.1% Xyl, 0.05% Fuc, 0.07% Glu | Increase in beneficial bacteria at all concentrations, without significant differences between 0.4% and 0.5%. No inhibition was detected against pathogens | Not provided | [ |
| In vivo trial using male Wistar rats (six per group) | Rats were pretreated with 0.5% carboxymethylcelloluse (controls) or 0.5% | Molar mass distribution was found to be within 2.6 × 106 and 3.8 × 105 g/mol, while the soluble carbohydrate, protein, and sulfate contents were 85.5%, 2.5%, and 8.4%, respectively | No relevant variation was observed in GM populations | Prevention of naproxen-induced gastrointestinal damage determined by macro- and microscopic findings | [ |
| In vitro fermentation system using fresh fecal samples from four healthy donors | 100 mg of sulphated polysaccharides obtained from | Average molecular weight 923.3 kDa, sugar content 0.11% | Increase of Bacteroidetes, | Increase in total SCFA and acetic, propionic and isobutyric acids | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | 1% | Average molecular weight 143.8 kDa | No significant changes in GM | Increase in total SCFA, acetic and propionic acids | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | 1% | Average molecular weight 20.1 kDa and 6.5 kDa, respectively | Only | Both | [ |
| In vitro fermentation system | 1% | Not provided | Increase in | Increase in SCFA | [ |
| In vitro fermentation system using fresh fecal samples from threehealthy donors | Extracts from | Not provided | Increase in | Increase in SCFA, acetic and propionic acids | [ |
Gal: galactose; Glc: glucose; GulA: guluronic acid; FOS: fructooligosaccharides; Fuc: fucose; GM. Gut microbiota; kDa: kilodaltons; Man: mannose; MRS: Man, Rogosa and Sharpe; MTCC: Microbial Type Culture Collection and Gene Bank; NCIM: National Centre of Integrative Medicine; SCFA: Short chain fatty acids; Xyl: Xylose,
Prebiotic effect of different species of green seaweed.
| Type of Study | Seaweed, Dosage and Time of Exposure | Polysaccharides Characterization | Significant Changes in Gut Microbiota | Significant Changes in Metabolites | Reference |
|---|---|---|---|---|---|
| In vivo trial using 36 C57BL/6J mice, 18 males and 18 females in different trials | Molecular weight 11.67 kDa; 14.7% sulfate content. Monosaccharide composition: 1.0% Man, 49.7% Rha, 10.8% GlcA; 29.9% Glc; 1.3% Gal; 7.2% Xyl | Increase of | [ | ||
| In vitro test comparing the growth of | 1% | 60.6% fiber, 16.9% protein, 1.2% fat, 25.4% ash. Monosaccharide content included cellobiose, fructose, glucose and maltose | Prebiotic effect by 1.44-fold more growth stimulation of | Not provided | [ |
| In vivo trial using 24 male C57BL/6J mice | Polysaccharides extracted from | Not provided | Polysaccharides supplementation decreased Tenericutes, and Cyanobacteria. At genus level, decreased | Not provided | [ |
| In vitro fermentation system using fresh fecal samples from three healthy donors | 0.8 g of fucoidans obtained from | Not provided | Decrease in | Not significant changes | [ |
| In vivo trial using 24 Kunming female mice | Loperamide at a dosage of 9.6 mg/kg/twice a day via oral gavage for 2 weeks was provided to mice to induce slow-transit constipation in mice. Afterwards, | Not provided | Both | [ | |
| In vivo trial using 24 Kunming male mice | Treated mice were fed with high sucrose/high fat diet for 5 weeks. Next type-2 diabetes was induced by intraperitoneal administration of streptozotocin at 45 mg/kg for 3 days. Diabetic mice were administered with 150 mg/kg | Not provided | Flavonoids from | [ |
Gal: galactose; GlcA: glucuronic acid; Glc: glucose; GM: gut microbiota; kDa: kilodaltons; Man: mannose; MRS: man Rogosa and Sharpe; MTCC: Microbial Type Culture Collection and Gene Bank; NCIM: National Centre of Integrative Medicine; Rha: rhamnose; SCFA: Short chain fatty acids; Xyl: Xylose.